ArticleFrontiers in cardiovascular medicine2026
PCSK9 promotes atherosclerosis progression through the FOXO3a autophagy signaling pathway.
Article in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: The proprotein convertase subtilisin/kexin type 9 (PCSK9) has an impact on atherosclerosis by modulating the autophagy pathway; however, its precise mechanisms underlying autophagy require additional investigation. Methodology and results: ApoE-/- male mice were fed high-fat diets, different doses of COS (Chitosan oligosaccharide) or JY2 were given by gavage, and RAPA or CQ was injected intraperitoneally. The immunofluorescence intensities of PCSK9, FOXO3a and LC3, collagen fibers and calcium salt deposition in aortic sinus tissues were measured. Conclusions and significance: PCSK9 promotes macrophage autophagy injury and facilitates atherosclerosis progression through activation of the FOXO3a autophagy pathway, whereas COS reduces PCSK9 injury to macrophages and atherosclerosis. These findings provide a theoretical basis and experimental foundation for the future development of PCSK9 inhibitors as a new strategy for the treatment of As.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.